Enrupatinib (EI-1071): A Comprehensive Analysis of a Selective CSF-1R Inhibitor in Clinical Development

Executive Summary

Enrupatinib (EI-1071) is an investigational, orally bioavailable, and brain-penetrant small molecule engineered as a potent and highly selective inhibitor of the Colony Stimulating Factor-1 Receptor (CSF-1R).[1] Its primary clinical development program is focused on Alzheimer's disease (AD), where it aims to offer a novel disease-modifying therapeutic approach by modulating microglia-mediated neuroinflammation.[3] The rationale for this approach is supported by a growing body of evidence implicating neuroinflammation as a central pillar in the pathophysiology of AD.

The compound has successfully completed a Phase 1 first-in-human study in healthy volunteers, which established a favorable safety and tolerability profile, with all treatment-emergent adverse events in the multiple-dose cohort being mild and unrelated to the drug.[6] Building on these results, Elixiron Immunotherapeutics has initiated a Phase 2 proof-of-concept clinical trial in patients with AD (NCT06745583). This study is strategically designed to use biomarker endpoints, including advanced neuroimaging, to validate target engagement in the central nervous system before proceeding to larger, more resource-intensive efficacy trials.[8]

Beyond neurodegeneration, Enrupatinib has demonstrated significant therapeutic potential in preclinical models of other diseases. It has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of Idiopathic Pulmonary Fibrosis (IPF), based on its ability to ameliorate lung fibrosis in animal models.[10] Furthermore, its capacity to reprogram the tumor microenvironment by depleting immunosuppressive tumor-associated macrophages has been demonstrated in oncology models, suggesting potential as a combination therapy with immune checkpoint inhibitors.[11] This report provides a comprehensive analysis of Enrupatinib's chemical properties, mechanism of action, preclinical data, and clinical development strategy, assessing its position within the therapeutic landscape and outlining key future milestones.

Compound Profile and Medicinal Chemistry

Identification and Nomenclature

The investigational compound is identified by the International Nonproprietary Name (INN) Enrupatinib.[2] Throughout its development, it has been referred to by several codes, most prominently EI-1071 (and its variants EI 1071, EI1071) used by the primary developer, Elixiron Immunotherapeutics.[1] Other identifiers include 4B71-01 and FB-1071, the latter of which is used in clinical trials conducted in China.[3] The compound is cataloged in major drug databases under DrugBank ID DB18486 and has been assigned the Chemical Abstracts Service (CAS) Registry Number 2222689-47-4.[2] Its formal chemical name under IUPAC nomenclature is 6-[3-methoxy-4-[(6-methylpyridin-3-yl)methoxy]anilino]-3-morpholin-4-ylquinoxaline-5-carbonitrile.[13]

Chemical Structure and Physicochemical Properties

Enrupatinib is classified as a small molecule drug.[1] Its molecular formula is $C_{27}H_{26}N_{6}O_{3}$, corresponding to a molecular weight of approximately 482.54 g/mol.[2] In its solid state, it appears as a light yellow to green yellow powder and demonstrates solubility in organic solvents such as dimethyl sulfoxide (DMSO).[2] The compound's structure is unambiguously defined by its Canonical SMILES string (CC1=CC=C(C=N1)COC2=CC=C(C=C2OC)NC3=CC=C4C(=C3C#N)N=C(C=N4)N5CCOCC5) and InChIKey (UGKFKFGVNJJPOL-UHFFFAOYSA-N), which facilitate its identification in chemical and patent databases.[3]

Table 1: Key Identifiers and Physicochemical Properties of Enrupatinib

Property	Value	Source(s)
Generic Name (INN)	Enrupatinib	2
Development Codes	EI-1071, EI 1071, EI1071, 4B71-01, FB-1071	1
DrugBank ID	DB18486	[1, 14]
CAS Registry No.	2222689-47-4	[2, 13]
IUPAC Name	6-[3-methoxy-4-[(6-methylpyridin-3-yl)methoxy]anilino]-3-morpholin-4-ylquinoxaline-5-carbonitrile	13
Molecular Formula	$C_{27}H_{26}N_{6}O_{3}$	[2, 3, 20]
Molecular Weight	482.54 g/mol	[2]
Type	Small Molecule	1
Appearance	Solid, light yellow to green yellow powder	2

Development History and Corporate Ownership

Enrupatinib was originally discovered and developed by the Development Center for Biotechnology (DCB) in Taiwan, a notable achievement showcasing the region's advancing capabilities in novel drug discovery.[22] Subsequently, the portfolio for EI-1071 was exclusively licensed to Elixiron Immunotherapeutics, Inc., a US-based clinical-stage biotechnology company with a strategic focus on developing next-generation immunotherapies.[22]

The corporate structure surrounding the drug's development appears to involve regional partnerships. While Elixiron leads the primary development efforts, particularly in the United States and Taiwan, other entities are also associated with the compound. 4B Technologies (Beijing) Co., Limited is listed as an originator and active organization, while Fubei Biotechnology Suzhou Co. Ltd. is noted as a license organization.[3] This structure, combined with the use of a distinct development code (FB-1071) in Chinese clinical trial registries [3], strongly suggests a bifurcated development strategy. It is likely that a Chinese partner is managing clinical development, regulatory filings, and eventual commercialization within Greater China, operating in parallel with Elixiron's core program focused on Alzheimer's disease for Western markets. Such an arrangement can accelerate regional progress and access but may introduce complexities regarding global data integration, regulatory harmonization, and brand strategy in the future.

Mechanism of Action and Pharmacological Rationale

The Colony Stimulating Factor-1 Receptor (CSF-1R) Pathway

Enrupatinib's therapeutic activity is derived from its targeted inhibition of the Colony Stimulating Factor-1 Receptor (CSF-1R), also known as c-FMS.[11] CSF-1R is a member of the Class III receptor tyrosine kinase (RTK) family, which also includes other critical signaling proteins such as c-KIT, FMS-like tyrosine kinase-3 (FLT3), and platelet-derived growth factor receptors (PDGFRs).[25] The CSF-1R pathway is activated upon binding of its cognate ligands, CSF-1 (macrophage colony-stimulating factor) or Interleukin-34 (IL-34). This ligand binding induces receptor dimerization and autophosphorylation of its intracellular kinase domain, initiating downstream signaling cascades that are fundamental for the differentiation, proliferation, survival, and function of myeloid lineage cells.[25] Key cell types dependent on this pathway include tissue-resident macrophages, microglia (the resident immune cells of the central nervous system), and osteoclasts, which are involved in bone resorption.[11]

Pharmacodynamics: Potency and Kinase Selectivity of Enrupatinib

A defining characteristic of Enrupatinib is its combination of high potency and exceptional selectivity for CSF-1R. In vitro assays demonstrate that the drug inhibits CSF-1R with a half-maximal inhibitory concentration ($IC_{50}$) of 3 nM.[11] This potency is superior to that of pexidartinib (PLX3397), an approved CSF-1R inhibitor, which has a reported $IC_{50}$ of 10 nM.[11]

Even more significant is the drug's selectivity profile. In a broad kinase panel screening of 468 assays, Enrupatinib displayed potent, nanomolar-level inhibition of CSF-1R while showing negligible activity against 453 other non-mutant kinases at a concentration of 1 µM.[11] This high degree of specificity is particularly evident when compared to other structurally related Class III RTKs. The compound exhibits greater than 100-fold selectivity over cKit, over 450-fold selectivity over Flt3, over 220-fold selectivity over PDGFRα, and over 6000-fold selectivity over PDGFRβ.[11] This "clean" kinase profile is a crucial molecular attribute. Many kinase inhibitors are limited by off-target toxicities stemming from the inhibition of related kinases. The remarkable selectivity of Enrupatinib minimizes the potential for such off-target effects, which directly contributes to the favorable safety profile observed in both comprehensive preclinical toxicology studies and the first-in-human clinical trial. This robust safety signal is what de-risks the compound's development and provides the confidence to pursue indications requiring chronic administration, such as Alzheimer's disease.

Cellular Consequences of CSF-1R Inhibition in Key Tissues

The potent and selective inhibition of CSF-1R by Enrupatinib translates into distinct and therapeutically relevant effects on specific cell populations in different tissues.

Modulation of Microglia and Neuroinflammation

A cornerstone of the Enrupatinib program is its ability to penetrate the blood-brain barrier and act on microglia within the central nervous system.[2] In the context of Alzheimer's disease, microglia can adopt an activated, pro-inflammatory state, particularly in the vicinity of amyloid plaques, contributing to a cycle of neuroinflammation and neuronal damage.[5] Preclinical studies show that Enrupatinib effectively modulates this process. It significantly reduces the population of activated, plaque-associated microglia while having a lesser effect on homeostatic microglia, thereby preserving their essential surveillance functions.[6] This targeted immunomodulation leads to a downstream reduction in neuroinflammatory gene expression, including key markers like Trem2 and Iba1, and ultimately protects against neuronal injury.[6]

Reprogramming of Tumor-Associated Macrophages (TAMs)

Within the tumor microenvironment (TME), CSF-1R signaling is a critical survival pathway for tumor-associated macrophages (TAMs), particularly those of the M2 phenotype.[11] These M2 TAMs are largely considered pro-tumorigenic, as they suppress anti-tumor immune responses and promote angiogenesis and metastasis.[11] By blocking CSF-1R, Enrupatinib disrupts this survival signal, leading to a reduction in TAM infiltration into the tumor. This action helps to reprogram the TME from an immunosuppressive to an immune-permissive state, thereby enhancing the efficacy of other immunotherapies.[11]

Impact on Other Myeloid Cells

The drug's mechanism extends to other CSF-1R-dependent cells. In vitro bioassays have confirmed that Enrupatinib inhibits CSF-1R activity in human monocytes, leading to a reduction in their proliferation.[11] It also effectively inhibits the differentiation of osteoclast precursors, a process heavily reliant on CSF-1R signaling, which suggests potential applications in bone-related pathologies.[11] In the lungs, pulmonary macrophages play a role in driving inflammation and tissue remodeling in fibrotic diseases. Enrupatinib's ability to regulate these cells forms the basis of its investigation for Idiopathic Pulmonary Fibrosis.[10]

Preclinical Profile: Efficacy, Pharmacokinetics, and Safety

In Vitro and In Vivo Pharmacokinetic (ADME) Profile

Enrupatinib has demonstrated a favorable absorption, distribution, metabolism, and excretion (ADME) profile in preclinical studies, indicating its suitability as an orally administered therapeutic. The compound is described as orally active and bioavailable, with high permeability in Caco-2 cell monolayer assays ($P_{app}$ A→B: $6.05 \times 10^{-6}$ cm/s), which is predictive of efficient absorption from the gastrointestinal tract.[11] A critical feature for its primary indication is its demonstrated ability to penetrate the blood-brain barrier, allowing it to reach its target cells (microglia) within the central nervous system.[2]

The molecule shows good metabolic stability in liver hepatocyte assays across multiple species, with a half-life ($T_{1/2}$) of 212.8 minutes in human hepatocytes.[11] Its potential for drug-drug interactions appears low, as it shows minimal inhibition of most major cytochrome P450 (CYP) enzymes, with $IC_{50}$ values greater than 50 µM for CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Some moderate interaction was noted with CYP3A4 ($IC_{50}$ of 11.83 µM with midazolam as the substrate), which warrants consideration in clinical use.[11] The drug is highly bound to plasma proteins, with a free fraction in human plasma of 0.98%.[11]

Table 2: Summary of Preclinical ADME and Pharmacokinetic Parameters

Parameter	Species	Value	Unit	Source(s)
Caco-2 Permeability ($P_{app}$ A→B)	N/A	6.05	$\times 10^{-6}$ cm/s	11
Plasma Protein Binding (% Free)	Human	0.98	%	11
	Rat	0.95	%	11
	Dog	0.62	%	11
Hepatocyte Stability ($T_{1/2}$)	Human	212.8	minutes	11
	Rat	101.3	minutes	11
	Dog	182.7	minutes	11
CYP Inhibition ($IC_{50}$)	Human	>50	µM	11
(CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6)
CYP3A4 Inhibition ($IC_{50}$)	Human	11.83	µM	11
(Substrate: Midazolam)

Preclinical Efficacy in Neurodegenerative Disease Models

In the 5xFAD transgenic mouse model, which recapitulates key features of Alzheimer's disease pathology, treatment with Enrupatinib demonstrated significant therapeutic effects. The compound led to a marked improvement in cognitive function, as measured by performance in the novel object recognition (NOR) and Y-maze tests.[6] These behavioral improvements were mechanistically linked to pathological changes in the brain, including a significant reduction in activated microglia and neuroinflammation. Furthermore, treatment showed a trend towards a reduction in amyloid plaque burden and neuronal death, providing strong preclinical validation for its disease-modifying potential in AD.[2]

Preclinical Efficacy in Oncology Models

The initial development work for Enrupatinib highlighted its potential as an immuno-oncology agent. In syngeneic mouse models of cancer, oral administration of Enrupatinib at 100 mg/kg effectively reduced the infiltration of pro-tumor TAMs in both MC38 colorectal tumors and EMT6 breast tumors.[11] Critically, Enrupatinib demonstrated synergy with immune checkpoint blockade. When dosed in combination with an anti-PD-1 antibody, it produced an enhanced anti-tumor effect compared to either agent alone, supporting the hypothesis that reprogramming the tumor microenvironment can augment the efficacy of T-cell-directed immunotherapies.[11]

Preclinical Efficacy in Idiopathic Pulmonary Fibrosis (IPF) Models

The rationale for investigating Enrupatinib in IPF stems from the central role of pulmonary macrophages in driving the inflammatory and fibrotic processes that characterize the disease.[10] In preclinical animal models of IPF, blockade of the CSF-1R pathway with Enrupatinib yielded promising results, showing an amelioration of lung fibrosis and an improvement in respiratory function.[10] These findings provided the basis for the FDA's decision to grant the compound Orphan Drug Designation for this indication.

Comprehensive Preclinical Safety and Toxicology Assessment

Enrupatinib has undergone extensive preclinical safety evaluation and has demonstrated a generally well-tolerated profile.

• Cardiovascular Safety: In dedicated studies in beagle dogs, no adverse findings were noted on electrocardiograms (ECG) or blood pressure. Furthermore, the drug showed a low risk of causing cardiac arrhythmias, with an $IC_{50}$ for the hERG ion channel of >62.17 µM.[11]
• Central Nervous System (CNS) Safety: A functional observational battery in Sprague-Dawley (SD) rats revealed no CNS-related adverse effects.[11]
• Genotoxicity: The compound was found to be non-mutagenic in a standard panel of genotoxicity tests, including the bacterial reverse mutation (Ames) test and an in vitro chromosome aberration assay.[11]
• Repeat-Dose Toxicology: 28-day repeat-dose studies were conducted in two species. In rats, no adverse effects were observed, establishing a No Observed Adverse Effect Level (NOAEL) of 450 mg/kg.[11] In dogs, the NOAEL was lower, at 50 mg/kg, with observations of mononuclear cell infiltration and bile pigment in the liver at higher doses.[11]

The observation of liver findings in dogs, a species often considered more predictive of human hepatotoxicity than rodents, is noteworthy. While the 28-day rat study was clean, this species-specific signal warrants careful attention. The competitor CSF-1R inhibitor, pexidartinib, carries an FDA black box warning for the risk of serious and potentially fatal liver injury.[26] Although the Phase 1 human trial of Enrupatinib in healthy volunteers did not reveal safety concerns, the preclinical dog data underscores the necessity for vigilant monitoring of liver function tests in all ongoing and future clinical trials, especially those involving longer-term dosing in patient populations. Establishing a superior liver safety profile compared to pexidartinib would represent a significant clinical and commercial advantage for Enrupatinib.

Clinical Development and Trial Analysis

Phase 1 First-in-Human Study (NCT04238364): Design and Key Safety Findings

Enrupatinib's clinical journey began with a first-in-human Phase 1 trial (NCT04238364) designed to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers.[6] The study, which was successfully completed in 2021, enrolled 58 participants and employed a standard dose-escalation design, comprising both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts.[4]

The primary outcome of the study was positive, with Enrupatinib demonstrating that it was well-tolerated. In the MAD portion of the trial, all reported treatment-emergent adverse events (TEAEs) were classified as Grade 1 (mild) in severity and were assessed by investigators as being unrelated to the study drug.[6] These favorable results established a strong safety foundation for the compound and supported the decision to advance its development into patient populations for chronic diseases like Alzheimer's.[6]

Phase 2 Proof-of-Concept Study in Alzheimer's Disease (NCT06745583): A Detailed Analysis

Building on the successful Phase 1 trial, Elixiron has initiated a Phase 2 study (NCT06745583) to investigate Enrupatinib in its primary target indication of Alzheimer's disease.

Study Design, Patient Population, and Endpoints

The trial is an open-label, exploratory, non-randomized, single-group assignment study designed as a proof-of-concept investigation.[3] Sponsored by Elixiron Immunotherapeutics, the study is actively recruiting an estimated 15 participants at Taipei Veterans General Hospital in Taiwan.[3] The target population consists of male and female subjects aged 50 to 85 years with a clinical diagnosis of mild, moderate, or severe AD, defined by NIA-AA criteria and a Clinical Dementia Rating (CDR) score of $\geq0.5$.[8] Participants will receive an oral dose of 448.2 mg of EI-1071 twice daily for 28 days.[8] The study is estimated to run from December 2024 to June 2026.[8]

Strategic Importance of Biomarker-Driven Outcomes

The design of this Phase 2 trial represents a highly strategic, modern, and capital-efficient approach to drug development in the challenging field of neurodegeneration. Rather than focusing on clinical efficacy endpoints like cognitive scores, which would require a large, long, and costly trial, this study is centered on biomarker-based proof-of-mechanism.[8]

The primary goal is to validate that Enrupatinib engages its target in the human brain and produces the intended biological effect. This will be assessed directly by measuring the change in activated microglia using Positron Emission Tomography (PET) imaging with a tracer for the 18 kDa translocator protein (TSPO), a marker upregulated in activated microglia and astrocytes.[8] A secondary goal is to evaluate the drug's effect on a panel of inflammatory biomarkers in blood and/or cerebrospinal fluid that are associated with AD progression.[8] By focusing on these objective biological readouts in a small cohort over a short duration, Elixiron can obtain a clear go/no-go signal. A positive result, demonstrating a reduction in the TSPO PET signal, would provide strong evidence of target engagement and significantly de-risk the program, attracting the investment and partnerships necessary for a large-scale pivotal Phase 3 trial. Conversely, a negative result would allow for an early termination of the program, saving substantial resources.

Analysis of Other Registered Phase 1 Studies (FB-1071)

In parallel with the main development program, at least two Phase 1 studies have been registered in China using the development code FB-1071, further evidencing a regional development strategy.

• CTR20230290: A recruiting, randomized, double-blind, placebo-controlled Phase 1 study designed to evaluate the safety, tolerability, and pharmacokinetics of a single dose of FB-1071 in healthy adult Chinese subjects.[3]
• CTR20230343: A completed Phase 1 study that investigated the effect of food on the pharmacokinetics of an oral dose of FB-1071 in healthy adult Chinese subjects.[3]

Table 3: Overview of the Enrupatinib Clinical Trial Program

Trial ID	Drug Code	Phase	Status	Population	N	Design	Primary Objectives / Goal
NCT04238364	EI-1071	1	Completed	Healthy Volunteers	58	SAD/MAD	Assess safety, tolerability, and PK
NCT06745583	EI-1071	2	Recruiting	AD Patients	15	Open-label, single-arm	Assess safety and proof-of-mechanism via TSPO PET imaging and biomarkers
CTR20230290	FB-1071	1	Recruiting	Healthy Chinese Volunteers	N/A	Randomized, placebo-controlled	Assess safety, tolerability, and PK of a single dose
CTR20230343	FB-1071	1	Completed	Healthy Chinese Volunteers	N/A	Open-label	Assess food effect on PK

Therapeutic Landscape and Strategic Assessment

Primary Indication: Alzheimer's Disease

Rationale and Potential for Disease Modification

The strategic pivot of Enrupatinib's development towards Alzheimer's disease aligns with the evolving scientific consensus that neuroinflammation is not merely a consequence of neurodegeneration but a critical driver of the disease process, alongside amyloid-beta and tau pathologies.[30] By targeting microglia, the primary immune effectors in the brain, Enrupatinib represents a promising disease-modifying strategy.[5] Its mechanism is distinct from and potentially complementary to anti-amyloid antibody therapies, offering an opportunity to address a different aspect of the complex pathophysiology of AD.[12]

Competitive Landscape of Neuroinflammation-Targeting Therapies

Enrupatinib is entering a dynamic but challenging therapeutic area. While the field of neuroinflammation in AD is burgeoning with various approaches (e.g., TREM2 agonists, NLRP3 inflammasome inhibitors), the landscape of CSF-1R inhibitors specifically for AD is less crowded. The key competitive advantages for Enrupatinib will be its demonstrated brain penetrance, high selectivity, favorable safety profile established in Phase 1, and convenient oral route of administration, which is particularly important for a chronic disease requiring long-term treatment.

Secondary and Exploratory Indications

Elixiron appears to be pursuing a "beachhead" strategy, leveraging the validated biology of CSF-1R inhibition in rarer diseases to secure regulatory advantages and build corporate value, while dedicating its primary resources to the high-risk, high-reward AD indication.

Idiopathic Pulmonary Fibrosis (IPF)

On August 2, 2022, the U.S. FDA granted Orphan Drug Designation to EI-1071 for the treatment of IPF.[10] This designation provides valuable development incentives, including potential market exclusivity, tax credits, and waiver of application fees. The designation was supported by compelling preclinical data showing that Enrupatinib could ameliorate lung fibrosis.[10] Despite this regulatory milestone, there are currently no active clinical trials for Enrupatinib in IPF, suggesting that this indication may be pursued at a later date or represents an opportunity for a strategic partnership.[3]

Tenosynovial Giant Cell Tumor (TGCT)

TGCT is a rare, benign tumor of the joints characterized by the overexpression of the CSF1 ligand, making it an ideal target for CSF-1R inhibitors.[28] The therapeutic hypothesis is clinically validated, with two FDA-approved drugs for this indication: pexidartinib (Turalio) and, more recently, vimseltinib (Romvimza).[28] Enrupatinib is listed in industry pipeline reports as being in development for TGCT.[35] Its primary path to market in this space would be to demonstrate a superior safety profile, particularly in relation to the known risk of hepatotoxicity associated with pexidartinib.[28]

Table 4: Competitive Landscape of CSF-1R Inhibitors in Development and on Market

Drug Name	Company	Approved/Highest Phase	Key Indication(s)	Potency (IC50​)	Key Differentiators / Safety Issues
Enrupatinib (EI-1071)	Elixiron Immunotherapeutics	Phase 2	AD, IPF, TGCT	3 nM	High selectivity; Favorable Phase 1 safety; Brain-penetrant
Pexidartinib (Turalio)	Daiichi Sankyo	Approved	TGCT	10 nM	First-in-class oral agent for TGCT; Black box warning for hepatotoxicity
Vimseltinib (Romvimza)	Daiichi Sankyo	Approved	TGCT	N/A	Selective inhibitor; Favorable safety profile vs. pexidartinib; No cholestatic hepatotoxicity observed

Oncology

The initial preclinical research for Enrupatinib provided a strong rationale for its use in immuno-oncology.[11] Its ability to deplete immunosuppressive TAMs and synergize with anti-PD-1 therapy positions it as a promising candidate for combination treatments across various solid tumors. However, the company's current clinical focus has clearly shifted away from oncology and towards neuroinflammatory and immunological diseases. This area remains a significant opportunity for future development, most likely through out-licensing or partnership with a larger oncology-focused company.

Elixiron Immunotherapeutics: Corporate Strategy and Partnerships

Elixiron has demonstrated strategic acumen in advancing the Enrupatinib program. The company has successfully secured substantial non-dilutive funding and prestigious validation from the Alzheimer's Association's "Part the Cloud" program, which is supported by Bill Gates, receiving at least $1.8 million across two grants to fund the Phase 1 and Phase 2 trials.[3] The drug has also gained recognition from the Bill Gates-founded Global Neurodegeneration Proteomics Consortium.[12] This external validation is a powerful signal of scientific merit to the broader investment community. To fund its clinical ambitions, Elixiron has also completed pre-B and B rounds of venture financing from a consortium of investors, including the international Lotte Holdings.[12] The company's pipeline clearly prioritizes Enrupatinib for AD, while listing other indications like IPF and Amyotrophic Lateral Sclerosis (ALS) as earlier-stage opportunities, with a named partner (4B Technologies) for ALS.[42]

Synthesis, Outlook, and Recommendations

Integrated SWOT Analysis of the Enrupatinib Program

• Strengths: Enrupatinib possesses a compelling molecular profile, characterized by high potency and exceptional kinase selectivity. It is orally bioavailable and brain-penetrant, with a robust preclinical data package demonstrating efficacy across neurodegeneration, fibrosis, and oncology models. Crucially, it has an excellent safety profile from its completed Phase 1 trial, supported by prestigious external validation and non-dilutive funding.
• Weaknesses: The ongoing Phase 2 trial's open-label design, while efficient for testing mechanism, will not be able to control for placebo effects on any subjective or clinical measures. The preclinical toxicology data revealed a species-specific liver signal in dogs, which, although not seen in humans yet, requires diligent monitoring. The company's valuation appears heavily reliant on the success of this single lead asset in a high-risk indication.
• Opportunities: The drug has the potential to be a first-in-class disease-modifying therapy for Alzheimer's disease by targeting neuroinflammation. It also has a clear opportunity to establish a best-in-class safety profile in the validated TGCT market. The significant unmet medical need in IPF, backed by an Orphan Drug Designation, and the broad potential in immuno-oncology represent substantial future value-creation opportunities.
• Threats: The primary threat is the historically high rate of clinical trial failure in Alzheimer's disease. Competition within the neuroinflammation space is growing, and there is always a risk of unforeseen long-term safety issues emerging with chronic dosing. The complex corporate and licensing structure could also pose future strategic challenges.

Key Inflection Points and Future Development Milestones

The trajectory of the Enrupatinib program will be defined by several key upcoming events.

• Near-Term (12-24 months): The most critical near-term inflection point will be the readout of the top-line data from the Phase 2 AD trial (NCT06745583), expected after March 2026. The results from the TSPO PET imaging and fluid biomarker analyses will be paramount. This data will provide the first direct evidence of target engagement in the brains of AD patients and will be the single most significant determinant of the program's future.
• Mid-Term (2-4 years): A positive outcome from the Phase 2 study would trigger a decision on the design and initiation of a large, global, pivotal Phase 3 study in AD. In this timeframe, the company may also elect to initiate Phase 2 studies in either IPF or TGCT, potentially with a strategic partner to share costs and risk.
• Long-Term: The ultimate long-term goal is the submission of regulatory applications (e.g., a New Drug Application to the FDA) for marketing approval in one or more of its target indications.

Concluding Assessment and Strategic Recommendations

Enrupatinib (EI-1071) is a scientifically compelling and well-differentiated CSF-1R inhibitor with best-in-class potential rooted in its high potency and selectivity. The development program, steered by Elixiron Immunotherapeutics, is strategically sound, focusing on the high-impact field of Alzheimer's disease while employing a modern, biomarker-driven approach to mitigate risk. The primary challenge is not the drug itself, but the formidable nature of the AD indication.

For all stakeholders, the key recommendation is to focus intently on the biomarker data from the ongoing Phase 2 trial. This readout will serve as the crucial proof-of-concept and will be the most reliable predictor of the drug's ultimate probability of success. The secondary indications, particularly IPF and TGCT, should be viewed as valuable, lower-risk strategic assets. They provide diversification, a potential faster path to a first market approval, and significant partnership opportunities that can fund the more ambitious and long-term development in Alzheimer's disease.

Works cited

1. EI-1071: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed November 1, 2025, https://go.drugbank.com/drugs/DB18486
2. EI-1071 (Enrupatinib) | CSF1R inhibitor | Probechem Biochemicals, accessed November 1, 2025, https://www.probechem.com/products_EI-1071.html
3. Enrupatinib - Drug Targets, Indications, Patents - Patsnap Synapse, accessed November 1, 2025, https://synapse.patsnap.com/drug/5b990651e9064316a8790e61846da8c5
4. EI-1071, Elixiron's drug candidate targeting microglia-induced inflammation for treating Alzheimer's disease has received the approval for a clinical trial in Taiwan, accessed November 1, 2025, https://elixiron.com/news-detail.php?id=27&lang=en
5. Elixiron Immunotherapeutics Awarded Alzheimer's Association Grant to Target Microglia in Alzheimer's Disease - FirstWord Pharma, accessed November 1, 2025, https://firstwordpharma.com/story/5091201
6. Safety of the CSF1R Inhibitor EI‐1071 in Human and Its ... - NIH, accessed November 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11713459/
7. (PDF) Safety of the CSF1R Inhibitor EI‐1071 in Human and Its Pharmacological Effects to Reduce Neuroinflammation and Improve Memory Function in a Mouse Model of Alzheimer's Disease - ResearchGate, accessed November 1, 2025, https://www.researchgate.net/publication/387856211_Safety_of_the_CSF1R_Inhibitor_EI-1071_in_Human_and_Its_Pharmacological_Effects_to_Reduce_Neuroinflammation_and_Improve_Memory_Function_in_a_Mouse_Model_of_Alzheimer's_Disease
8. NCT06745583 | A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients | ClinicalTrials.gov, accessed November 1, 2025, https://clinicaltrials.gov/study/NCT06745583
9. Elixiron Immunotherapeutics to Initiate Phase 2 Clinical Trial of Innovative Alzheimer's Drug EI-1071 at Taipei Veterans General Hospital, accessed November 1, 2025, https://elixiron.com/news-detail.php?id=28&lang=en
10. Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis - BioSpace, accessed November 1, 2025, https://www.biospace.com/elixiron-immunotherapeutics-announces-orphan-drug-designation-granted-to-csf-1r-inhibitor-ei-1071-for-the-treatment-of-idiopathic-pulmonary-fibrosis
11. A POTENT AND SELECTIVE CFMS INHIBITOR EI-1071 INHIBITS CSF1R SIGNALING AND REGULATES THE TUMOR-ASSOCIATED MACROPHAGES - Elixiron Immunotherapeutics Inc., accessed November 1, 2025, https://www.elixiron.com/static/upload/file/20201001/EI1071_AACR2019.pdf
12. Elixiron Immunotherapeutics' New Drug EI-1071 Gains International Recognition, accessed November 1, 2025, https://www.taiwan-healthcare.org/en/news-detail?id=0t033oqv1guzjfpe
13. enrupatinib | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed November 1, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13489
14. Details of the Drug | DrugMAP, accessed November 1, 2025, https://drugmap.idrblab.net/data/drug/details/DMXAUB7
15. Enrupatinib | C27H26N6O3 | CID 134442338 - PubChem, accessed November 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/134442338
16. Data Sheet (Cat.No.T201165) | TargetMol, accessed November 1, 2025, https://www.targetmol.com/attachment/DataSheet/264724928220102740/T201165
17. Enrupatinib | CymitQuimica, accessed November 1, 2025, https://cymitquimica.com/products/TM-T201165/2222689-47-4/enrupatinib
18. Enrupatinib (EI‐1071) | CSF1R Inhibitor - MedchemExpress.com, accessed November 1, 2025, https://www.medchemexpress.com/enrupatinib.html
19. Data Sheet - ProbeChem.com, accessed November 1, 2025, https://www.probechem.com/userfiles/Products/PDF/PC-24951/PC-2495101/PC-2495101_DataSheet.pdf
20. ENRUPATINIB - precisionFDA, accessed November 1, 2025, https://precision.fda.gov/ginas/app/ui/substances/26d7e967-2f59-4a08-9205-9713e847100d
21. Enrupatinib (EI‐1071) | CSF1R Inhibitor - MedchemExpress.com, accessed November 1, 2025, https://www.medchemexpress.com/enrupatinib.html?locale=es-ES
22. Why Taipei—Stories-Content - Bio@Taipei, accessed November 1, 2025, https://biodriven.taipei/en/meetBio_stories_content.aspx?id=795ad45e-1af8-4cdf-878e-112387c1e9b0
23. Elixiron concocts $27m series A round - - Global Corporate Venturing, accessed November 1, 2025, https://globalventuring.com/corporate/elixiron-concocts-27m-series-a-round/
24. enrupatinib (EI-1071) / Elixiron Immunotherap, 4B Technologies - LARVOL DELTA, accessed November 1, 2025, https://delta.larvol.com/Products/?ProductId=1e6ecfbd-3ad7-43d3-90f8-727f6410a024
25. Discovery of BPR1R024, an Orally Active and Selective CSF1R Inhibitor that Exhibits Antitumor and Immunomodulatory Activity in a Murine Colon Tumor Model | Journal of Medicinal Chemistry - ACS Publications, accessed November 1, 2025, https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c01006
26. CSF-1R Inhibitors - Alzheimer's Drug Discovery Foundation, accessed November 1, 2025, https://www.alzdiscovery.org/uploads/cognitive_vitality_media/CSF-1R_Inhibitors_UPDATE_REPLACES_PEXIDARTINIB.pdf
27. About the Alzheimer's Association, accessed November 1, 2025, https://www.alz.org/partthecloud/downloads/ptcg-chen-layabstract-updated-final-(1).pdf
28. Therapeutic Targets a Group of Rare Tumors | The AACR, accessed November 1, 2025, https://www.aacr.org/patients-caregivers/progress-against-cancer/%E2%80%8Btargeting-a-group-of-rare-tumors/
29. A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients | Clinical Research Trial Listing - CenterWatch, accessed November 1, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06745583/a-phase-2-study-to-assess-the-safety-of-ei-1071-and-the-effects-of-ei-1071-on-neuroinflammation-in-alzheimers-disease-patients
30. Alzheimer's disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy? - PubMed Central, accessed November 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10272781/
31. Elixiron Immunotherapeutics Announces Orphan Drug Designation Granted to CSF-1R Inhibitor, EI-1071 for the Treatment of Idiopathic Pulmonary Fibrosis, accessed November 1, 2025, https://elixiron.com/news-detail.php?id=21&lang=en
32. Pulmonary Fibrosis Clinical Trials - Mayo Clinic Research, accessed November 1, 2025, https://www.mayo.edu/research/clinical-trials/diseases-conditions/pulmonary-fibrosis
33. August 2025 clinical trial highlights - Pulmonary Fibrosis Foundation, accessed November 1, 2025, https://www.pulmonaryfibrosis.org/patients-caregivers/education-resources/clinical-trials-blog/clinical-trials/2025/08/26/august-2025-clinical-trial-highlights
34. CSF1 Receptor Inhibitor Vimseltinib Approved for Tenosynovial Giant Cell Tumor, accessed November 1, 2025, https://www.aacr.org/patients-caregivers/progress-against-cancer/csf1-receptor-inhibitor-vimseltinib-approved-for-tenosynovial-giant-cell-tumor/
35. Elixiron Immunotherapeutics employs advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics from phage display and single human B cell cloning platforms, to develop innovative therapies for cancer and immunological diseases. See our Pipeline of therapeutics under development below to learn more about our commitment to bring better, next-generation as well as new first-in-class immunotherapies to patients., accessed November 1, 2025, https://www.elixiron.com/?tpcc=nltermsheet
36. Elixiron Immunotherapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Patsnap Synapse, accessed November 1, 2025, https://synapse.patsnap.com/organization/319ca197d4e74c8b75a40f4acbf58a62
37. Tenosynovial Giant Cell Tumors - Pipeline Insight, 2025 - Research and Markets, accessed November 1, 2025, https://www.researchandmarkets.com/reports/4989283/tenosynovial-giant-cell-tumors-pipeline
38. Tenosynovial Giant Cell Tumors, Global Pipeline Insight 2021 - GlobeNewswire, accessed November 1, 2025, https://www.globenewswire.com/news-release/2021/12/17/2354370/28124/en/Tenosynovial-Giant-Cell-Tumors-Global-Pipeline-Insight-2021-Players-Drug-Profiles-Therapeutics-Assessment-Inactive-Pipeline-Products-and-More.html
39. Tenosynovial Giant Cell Tumors Pipeline Landscape 2021 Featuring Emerging Drugs Vimseltinib (Deciphera Pharma) and EI-1071 (Elixiron Immunotherapeutics) - ResearchAndMarkets.com - Business Wire, accessed November 1, 2025, https://www.businesswire.com/news/home/20211217005460/en/Tenosynovial-Giant-Cell-Tumors-Pipeline-Landscape-2021-Featuring-Emerging-Drugs-Vimseltinib-Deciphera-Pharma-and-EI-1071-Elixiron-Immunotherapeutics---ResearchAndMarkets.com
40. Elixiron Immunotherapeutics Receives Grant From the Alzheimer's Association to Trial Microglia-Targeting Immunotherapy - FirstWord Pharma, accessed November 1, 2025, https://firstwordpharma.com/story/5613507
41. News-Elixiron Immunotherapeutics Receives Grant From the Alzheimer's Association to Trial Microglia-Targeting Immunotherapy - Taiwania Capital, accessed November 1, 2025, https://www.taiwaniacapital.com/en/news/category/news/2022/news220718
42. PIPELINE - Elixiron Immunotherapeutics Inc., accessed November 1, 2025, https://elixiron.com/pipeline.php?lang=en